Please enable JavaScript in your browser. 
Skip to main content
Drug Information Portal National Library of Medicine
       Home    Substance
Drug Name: UCART19
Description: Wikipedia: An experimental immunotherapy against leukemia using genetically modified T-cells developed by Cellectis. Unlike personalized medicine, UCART19 is hoped to be ?off-the-shelf?.[1] Developed for Chronic lymphocytic leukemia (CLL) and Acute lymphoblastic leukemia (ALL) 

Site Map, Contact Us, Copyright, Privacy, Accessibility
U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894
National Institutes of Health, Health & Human Services
Freedom of Information Act
Drug Information Portal Mobile Site
Last updated: Aug 2020